Histone Deacetylase (HDAC) Inhibitors Market Report 2026

Histone Deacetylase (HDAC) Inhibitors Market Overview

• Histone Deacetylase (HDAC) Inhibitors market size has reached to $1.32 billion in 2025 • Expected to grow to $1.89 billion in 2030 at a compound annual growth rate (CAGR) of 7.4% • Growth Driver: Rising Neurodegenerative Disorders Drive Growth In HDAC Inhibitors Market • Market Trend: Shuttle Pharmaceuticals Advances Cancer Treatment With New HDAC Inhibitor Patents • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Histone Deacetylase (HDAC) Inhibitors Market?

Histone deacetylase (HDAC) inhibitors refer to a class of compounds that block the activity of histone deacetylase enzymes. These enzymes are responsible for removing acetyl groups from histone proteins, which leads to a more condensed chromatin structure and reduced gene expression. HDAC inhibitors can promote hyperacetylation of histones, which generally leads to a more relaxed chromatin structure and increased accessibility of DNA for transcription factors. The main classes of histone deacetylase (HDAC) inhibitors are class i HDACs, class ii HDACs, class iii HDACs, and class iv HDACs. Class I HDACs are a group of histone deacetylases that primarily function in the regulation of gene expression by modifying chromatin structure. They are involved in various cellular processes and have been studied extensively for their potential therapeutic applications in cancer and other diseases. The various routes of administration are oral HDAC inhibitors and parenteral HDAC inhibitors. The various applications include oncology, neurology, and others used by several end users such as hospitals, academic and research institutes, pharmaceutical companies, and others.

What Is The Histone Deacetylase (HDAC) Inhibitors Market Growth Forecast?

The histone deacetylase (hdac) inhibitors market size is expected to see strong growth in the next few years. It will grow to $1.89 billion in 2030 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to increasing adoption of personalized cancer therapies, rising investments in epigenetic drug development, expansion of neurology-related hdac research, growing demand for targeted therapeutics, increasing regulatory approvals for novel hdac inhibitors. Major trends in the forecast period include increasing focus on targeted epigenetic therapies, rising development of selective hdac inhibitors, growing use of combination oncology treatments, expansion of precision medicine drug pipelines, enhanced emphasis on biomarker-driven drug discovery.

Global Histone Deacetylase (HDAC) Inhibitors Market Segmentation

1) By Class: Class I HDACs, Class II HDACs, Class III HDACs 2) By Route Of Administration: Oral HDAC Inhibitors, Parenteral HDAC Inhibitors 3) By Application: Oncology, Neurology, Other Applications 4) By End User: Hospitals, Academic And Research Institutes, Pharmaceutical Companies, Other End Users Subsegments: 1) By Class I HDACs: HDAC1, HDAC2, HDAC3, HDAC8 2) By Class II HDACs: HDAC4, HDAC5, HDAC6, HDAC7, HDAC9, HDAC10 3) By Class III HDACs (Sirtuins): SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, SIRT7

What Is The Driver Of The Histone Deacetylase (HDAC) Inhibitors Market?

The rising incidence of neurodegenerative disorders is expected to propel the growth of the histone deacetylase (HDAC) inhibitors market going forward. Neurodegenerative disorders, characterized by the progressive degeneration and death of neurons in the brain and spinal cord, lead to cognitive and motor dysfunction and include diseases such as Alzheimer's, marked by memory loss and cognitive decline due to amyloid plaques and tau tangles. The rising incidence of neurodegenerative disorders can be attributed to several factors, such as age, longevity, genetics, and environmental factors. Histone deacetylase (HDAC) inhibitors are being explored as potential treatments for neurodegenerative disorders due to their ability to modulate gene expression and provide neuroprotective effects. For instance, in August 2024, according to the Centers for Disease Control and Prevention, a US-based federal agency, in the United States, an estimated 6.7 million older adults are currently living with Alzheimer's disease, a number that is expected to rise to nearly 14 million by 2060. Therefore, the rising incidence of neurodegenerative disorders is driving the growth of the histone deacetylase (HDAC) inhibitors industry.

Key Players In The Global Histone Deacetylase (HDAC) Inhibitors Market

Major companies operating in the histone deacetylase (hdac) inhibitors market are Bristol-Myers Squibb Company, Novartis AG, Merck KGaA, Abcam plc, Pharmacyclics LLC, R&D Systems Inc., Tenaya Therapeutics Inc., Syndax Pharmaceuticals Inc., Italfarmaco SpA, InvivoGen Corporation, TCI Chemicals (India) Pvt. Ltd., 4SC AG, Medivir AB, Mirati Therapeutics Inc., Spectrum Pharmaceuticals Inc., Curis Inc., Acetylon Pharmaceuticals Inc., Oryzon Genomics SA, Xynomic Pharmaceuticals Inc., Celleron Therapeutics Ltd., Midatech Pharma PLC, Karus Therapeutics Ltd., Shenzhen Chipscreen Biosciences Co. Ltd.

Global Histone Deacetylase (HDAC) Inhibitors Market Trends and Insights

Major companies operating in the histone deacetylase (HDAC) inhibitors market are focused on developing innovative solutions, such as HDAC inhibitors for cancer treatment, to enhance efficacy and reduce side effects. Histone deacetylase (HDAC) inhibitors are a class of pharmaceutical compounds used in cancer treatment. They function by inhibiting the activity of HDAC enzymes, which generally remove acetyl groups from histone proteins. This inhibition leads to increased acetylation of histones, altering chromatin structure and influencing gene expression. For instance, in September 2023, Shuttle Pharmaceuticals Holdings Inc., a US-based company that develops first-in-class therapies for cancer, was awarded New HDAC Inhibitor Patents for Cancer Treatment by the U.S. Patent and Trademark Office. These innovative inhibitors are tailored to target specific HDAC enzymes implicated in cancer progression, aiming to disrupt aberrant gene expression patterns that contribute to tumor growth and metastasis. The patented compounds demonstrate enhanced potency and selectivity, minimizing off-target effects and improving safety profiles for patients undergoing treatment.

What Are Latest Mergers And Acquisitions In The Histone Deacetylase (HDAC) Inhibitors Market?

In June 2024, Italfarmaco SpA, a US-based pharmaceutical company partnered with Iktos SA for an undisclosed amount. With this partnership, they aim to accelerate drug discovery in non-oncological fields by leveraging AI to design advanced HDAC inhibitors. Iktos SA. is a France-based technology company that specializes in artificial intelligence solutions for medicinal chemistry and drug discovery.

Regional Outlook

North America was the largest region in the histone deacetylase (HDAC) inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Histone Deacetylase (HDAC) Inhibitors Market?

The histone deacetylase (HDAC) inhibitors market consists of sales of valproic acid, hydroxamic acids, cyclic peptides, short-chain fatty acids, and benzamides. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Histone Deacetylase (HDAC) Inhibitors Market Report 2026?

The histone deacetylase (hdac) inhibitors market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the histone deacetylase (hdac) inhibitors industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.